In 2023, the sold production of medicaments containing hormones but not antibiotics in Italy stood at a certain level leading to forecasted values of 442.67 million euros in 2024, stepping down to 405.33 million euros by 2028. Notably, there is a consistent year-on-year decline ranging around 2% to 3%, emphasizing a shrinking market over this period. The Compound Annual Growth Rate (CAGR) presents an average annual decrease, underscoring persistent contraction concerns.
Future trends to watch for include the impact of regulatory changes and healthcare policies, shifts in consumer preferences towards alternative treatments, and advancements in biotechnologies that may alter market dynamics.
